Fig. 4: Dynamic changes of gut microbiota in SCH patients.

A and B α diversity, is lower in SCH patients than in HCs (indicated by C) at baseline and was increased after risperidone treatment in SCH patients. C and D SCH patients show a higher level of Lachnoclostridium and a lower level of Romboutsia than HCs. E and F The correlation between the changes of Lachnoclostridium, Romboutsia and clinical improvement measured by PANSS-FSNS. FDR were used to correct the multiple testing. *p < 0.05, **p < 0.01, ***p < 0. 001.